Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TELO Stock Forecast 2025-2026
$1.41
Current Price
$48.48M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TELO Price Targets
+999.3%
To High Target of $15.50
+999.3%
To Median Target of $15.50
+999.3%
To Low Target of $15.50
TELO Price Momentum
+3.7%
1 Week Change
-0.7%
1 Month Change
-72.4%
1 Year Change
-65.8%
Year-to-Date Change
-75.8%
From 52W High of $5.82
+25.9%
From 52W Low of $1.12
📊 TOP ANALYST CALLS
Did TELO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Telomir is one of their latest high-conviction picks.
Latest TELO Stock Price Targets & Analyst Predictions
TELO has shown a year-to-date change of -65.8% and a 1-year change of -72.4%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for TELO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TELO Analyst Ratings
0
Buy
0
Hold
0
Sell
TELO Price Target Range
Low
$15.50
Average
$15.50
High
$15.50
Current: $1.41
Latest TELO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TELO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Telomir Pharmaceuticals Inc. (TELO) Competitors
The following stocks are similar to Telomir based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Telomir Pharmaceuticals Inc. (TELO) Financial Data
Telomir Pharmaceuticals Inc. has a market capitalization of $48.48M with a P/E ratio of -2.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -303.2%.
Valuation Metrics
Market Cap
$48.48M
Enterprise Value
$41.93M
P/E Ratio
-2.5x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+15.1%
Current Ratio
17.5x
Debt/Equity
1.3x
ROE
-303.2%
ROA
-167.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Telomir Pharmaceuticals Inc. (TELO) Business Model
About Telomir Pharmaceuticals Inc.
What They Do
Develops innovative therapeutic solutions for oncology.
Business Model
The company focuses on research and development of advanced medicines, primarily targeting oncology and autoimmune diseases. It generates revenue by advancing its drug candidates through clinical trials and ultimately bringing them to market, often collaborating with medical institutions to enhance the development process.
Additional Information
Telomir Pharmaceuticals operates within the biotechnology sector, contributing to healthcare innovations. Its emphasis on precision medicine and targeted therapies positions it as a key player in addressing unmet medical needs, impacting both healthcare providers and patients globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1
CEO
Mr. Erez Aminov
Country
United States
IPO Year
N/A
Website
telomirpharma.comTelomir Pharmaceuticals Inc. (TELO) Latest News & Analysis
Latest News
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) reported that its candidate Telomir-1 reduced PSA levels in prostate cancer cells in preclinical studies, supporting its potential in cancer treatment.
Why It Matters
Telomir-1's ability to lower PSA levels suggests potential effectiveness in prostate cancer treatment, enhancing Telomir's value and market position as it moves towards clinical trials.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ: TELO) announced that its compound Telomir-1 shows efficacy against aggressive leukemia cells, expanding its oncology profile beyond previously noted cancers.
Why It Matters
Telomir-1's efficacy in blood cancers enhances its potential market reach, signaling growth opportunities for Telomir Pharmaceuticals and possibly impacting stock performance positively.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) reported that its compound Telomir-1 significantly reduces intracellular iron levels in human keratinocytes, outperforming Deferoxamine in preclinical studies.
Why It Matters
Telomir-1's ability to reduce intracellular iron levels more effectively than the gold-standard chelator may enhance its therapeutic potential, attracting investor interest in Telomir Pharmaceuticals' future.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) announced a binding LOI to acquire TELI Pharmaceuticals, securing global rights to its lead therapy, Telomir-1, and enabling up to $5M in shareholder contributions.
Why It Matters
Telomir's acquisition of TELI Pharmaceuticals enhances its pipeline with a promising therapy, potentially boosting long-term value and attracting shareholder investment, which can positively influence stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals reported preclinical data showing that Telomir-1 affects CASP8 and GSTP1 genes, which are crucial for cell death and detoxification, in a study on aggressive prostate cancer models.
Why It Matters
The findings on Telomir-1's effects on critical cancer-related genes could indicate potential breakthroughs in cancer therapies, impacting Telomir Pharmaceuticals' stock performance and market positioning.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Telomir Pharmaceuticals (NASDAQ:TELO) reported new findings showing that Telomir-1 effectively kills aggressive pancreatic cancer cells, supporting previous results in TNBC and prostate cancer models.
Why It Matters
Telomir-1's effectiveness against pancreatic cancer, along with its impact on other cancer types, suggests potential for significant market value and investor interest in Telomir Pharmaceuticals.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About TELO Stock
What is Telomir Pharmaceuticals Inc.'s (TELO) stock forecast for 2026?
Based on our analysis of 0 Wall Street analysts, Telomir Pharmaceuticals Inc. (TELO) has a median price target of $15.50. The highest price target is $15.50 and the lowest is $15.50.
Is TELO stock a good investment in 2026?
Analyst ratings for TELO are not currently available. The stock is currently trading at $1.41. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TELO stock?
Wall Street analysts predict TELO stock could reach $15.50 in the next 12 months. This represents a 999.3% increase from the current price of $1.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Telomir Pharmaceuticals Inc.'s business model?
The company focuses on research and development of advanced medicines, primarily targeting oncology and autoimmune diseases. It generates revenue by advancing its drug candidates through clinical trials and ultimately bringing them to market, often collaborating with medical institutions to enhance the development process.
What is the highest forecasted price for TELO Telomir Pharmaceuticals Inc.?
The highest price target for TELO is $15.50 from at , which represents a 999.3% increase from the current price of $1.41.
What is the lowest forecasted price for TELO Telomir Pharmaceuticals Inc.?
The lowest price target for TELO is $15.50 from at , which represents a 999.3% increase from the current price of $1.41.
What is the overall TELO consensus from analysts for Telomir Pharmaceuticals Inc.?
Analyst ratings for TELO are not currently available. The stock is trading at $1.41.
How accurate are TELO stock price projections?
Stock price projections, including those for Telomir Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 4:16 AM UTC